ArticleFrontiers in immunology2026
Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have improved outcomes in ovarian cancer with homologous recombination deficiency (HRD). However, approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are classified as homologous recombination-proficient (HRP), limiting the clinical benefit of PARPi in this population. Strategies capable of pharmacologically inducing a functional HRD-like state may expand the therapeutic scope of PARPi. Methods: A drug repurposing screen of 97 FDA-approved targeted agents was conducted in olaparib-insensitive HRP ovarian cancer cell models. Drug interactions were evaluated using cell viability and colony formation assays. Homologous recombination activity was assessed using RAD51 foci formation and DR-GFP reporter assays. DNA damage, cell cycle distribution, and apoptosis were analysed using immunofluorescence and flow cytometry. Antitumour efficacy was evaluated in xenograft models. Immune recognition-related features and susceptibility to CD8 Results: Proteasome inhibitors emerged as the most consistent sensitising drug class. The oral proteasome inhibitor ixazomib citrate demonstrated robust synergy with olaparib across multiple HRP ovarian cancer models. Mechanistically, ixazomib citrate disrupted recruitment of the homologous recombination protein RAD51 to DNA damage sites without reducing its expression, thereby inducing a functional HRD-like state consistent with BRCAness. This disruption increased olaparib-induced DNA damage, resulting in G2/M arrest and apoptosis. In xenograft models, combination therapy significantly suppressed tumour growth compared with either agent alone. Proteasome inhibition also increased tumour-surface MHC class I expression and appeared to enhance susceptibility to CD8 Conclusions: Ixazomib citrate sensitised HRP ovarian cancer models to PARP inhibition by functionally impairing homologous recombination repair. These findings provide preclinical support for proteasome inhibition as a PARPi-sensitising strategy in HRP ovarian cancer. The immune-related observations are based primarily on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.